Unicycive Therapeutics, Inc.
UNCY- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001766140
No open-market purchases or sales by Unicycive Therapeutics, Inc. insiders were filed in the last 90 days; 79 institutions reported holding it in 13F filings for Q2 2026, worth $54.6M in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Unicycive Therapeutics, Inc. as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 12
- −2 vs. Q2 2022
- Shares held
- 968.2K
- −207.5K (−17.6%) vs. Q2 2022
- Total value
- $571.0K
- −$405.0K (−41.5%) vs. Q2 2022
- New holders
- 1
- 3 more added
- Sold out
- 3
- 3 more reduced
1 institution that held it in Q2 2022 haven't filed for Q3 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting UNCY on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 79 | $54.6M |
| Q1 2026 | 51 | $65.2M |
| Q4 2025 | 35 | $47.5M |
| Q3 2025 | 30 | $27.4M |
| Q2 2025 | 20 | $24.6M |
| Q1 2025 | 29 | $34.5M |
| Q4 2024 | 31 | $49.0M |
| Q3 2024 | 29 | $19.1M |
| Q2 2024 | 24 | $9.52M |
| Q1 2024 | 23 | $31.6M |
| Q4 2023 | 16 | $11.3M |
| Q3 2023 | 16 | $12.2M |
| Q2 2023 | 15 | $1.38M |
| Q1 2023 | 13 | $3.54M |
| Q4 2022 | 9 | $428.3K |
| Q3 2022 | 12 | $571.0K |
| Q2 2022 | 15 | $992.0K |
| Q1 2022 | 12 | $1.48M |
| Q4 2021 | 12 | $2.30M |
| Q3 2021 | 10 | $3.02M |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Unicycive Therapeutics, Inc.; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Nantahala Capital Management, LLC | 710,542 | $419.0K | 0.04% | −19,138−2.6% | Reduced |
| Ayrton Capital LLC | 76,645 | $45.0K | 0.08% | 00.0% | Unchanged |
| Board of Trustees of The Leland Stanford Junior University | 63,019 | $37.0K | 0.00% | −184,564−74.5% | Reduced |
| Geode Capital Management, LLC | 26,109 | $15.0K | 0.00% | 00.0% | Unchanged |
| Vanguard Group Inc | 22,695 | $13.0K | 0.00% | 00.0% | Unchanged |
| Captrust Financial Advisors | 18,800 | $11.0K | 0.00% | +18,800 | New |
| Tandem Capital Management Corp | 15,500 | $10.0K | 0.01% | 00.0% | Unchanged |
| FineMark National Bank & Trust | 15,625 | $9.00K | 0.00% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 12,900 | $8.00K | 0.00% | +1,900+17.3% | Added |
| Tower Research Capital LLC (TRC) | 5,177 | $3.00K | 0.00% | +10+0.2% | Added |
| UBS Group AG | 1,190 | $1.00K | 0.00% | −3,301−73.5% | Reduced |
| Wells Fargo & Company | 45 | $0 | 0.00% | +9+25.0% | Added |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −15,210−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −5,000−100.0% | Sold out |
| Spire Wealth Management | 0 | $0 | 0.00% | −1,000−100.0% | Sold out |
| Frontier Wealth Management LLC | – | – | – | – | Not filed |